Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
Litigation Update: Medicare Drug Pricing Negotiations
Ashley C. Parrish
Join the Federalist Society for a webinar on the ongoing legal challenges to the Biden-era...
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
Lisa Larrimore Ouellette, Adam Mossoff, Dan Troy, Brad Watts
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Is the National Institute of Standards and Technology’s New Proposal on March-in a Price-Control Vehicle?
Walter Copan, Jeffrey E. Depp, Shubha Ghosh, Andrei Iancu, Brian O'Shaughnessy
The Biden Administration recently proposed new regulatory guidelines that would permit agencies to impose price...
Deep Dive Episode 155 – International Reference Pricing and Negotiation: Yes or No?
Adam Mossoff, Wendell Primus, Dean Reuter
Drug prices are a pressing policy issue. On November 20, 2020, President Donald Trump announced two new...
International Reference Pricing and Negotiation: Yes or No?
Adam Mossoff, Wendell Primus, Dean Reuter
Drug prices are a pressing policy issue. On November 20, 2020, President Donald Trump announced two new...